Competitive value of acquiring novel FDA product codes for medical device manufacturers: an original investigation.

Abstract

The FDA classifies medical devices by risk, assigning each a product code (PC) that determines its regulatory pathway for clearance. Novel PCs are created when new technologies raise safety or efficacy questions not addressed by existing codes. This analysis examines whether novel PCs provide strategic or regulatory advantages to first-mover manufacturers and how PC use evolves. Using FDA clearance data from 2000-2024, we analyzed the origin, usage patterns, and review timelines of novel PCs acr